Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 1, 2004, Pages 39-48

  Madeddu, Giordano ^a   Spanu, A ^a   Solinas, P ^a   Calia, G M ^a   Lovigu, C ^a   Chessa, F ^a   Mannazzu, M ^a   Falchi, A ^a   Mura, M S ^a   Madeddu, Giuseppe ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Bone density; Bone remodelling markers; Highly active antiretroviral therapy; Metabolic bone diseases; Osteoporosis; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIRETROVIRUS AGENT; CALCITRIOL; CALCIUM; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OSTEOCALCIN; PARATHYROID HORMONE; PROTEINASE INHIBITOR; PYRIDINIUM DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FEMALE; FEMUR; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; INTRAVENOUS DRUG ABUSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEX DIFFERENCE; STAGING; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; WORLD HEALTH ORGANIZATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; VITAMIN D;

EID: 4043075053     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Palella FJJ, Delaney KN, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient Study Investigator. N Engl J Med 1998;338:853-60.
2. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue theraphy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:25-32.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-2.
4. Rietshel P, Corcoran C, Stanley T, Basgoz N, Klinbansky A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240-4.
5. Grappin M, Piroth L, Verges B, Sgro C, Mack G, Buisson M et al. Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy [letter]. AIDS 2000;26:1070-2.
6. Calza L, Manfredi R, Chiodo F. Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy [letter]. J Acquit Immune Defic Syndr 2002;31:361-3.
7. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwar W, Teitelbaum SL et al. Accelerated bone mineral loss in HIV-infected patients potent antiretroviral therapy. AIDS 2000;14:F63-7.
8. Hoy J, Hudson J, Law M, Cooper DA. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with lipodystrophy syndrome and well controlled HIV viremia. Seventh Conference on Retroviruses and Opportunistic Infections. Conference Report; 2000 January 30 - February 4, San Francisco USA: 59.
9. Moore A, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al. Reduced bone density in HIV-positive individuals. AIDS 2001;15:1731-3.
10. Madeddu Gr, Spanu A, Solinas P, Calia GM, Lovigu C, Mannazzu M et al. Bone mass loss risk in HIV-infected patients treated with highly active antiretroviral therapy including protease inhibitors. Antiviral Ther 2001;6 Suppl 4:56.
11. Huang JS, Rietschel P, Hadigan CM, Rosenthal DL, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001;15: 975-82.
12. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001;15:1823-9.
13. Carr A, Miller J, Eisman JA, Cooper DA, Osteopenia in HIV infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001;15:703-9.
14. Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al. Stable or increasing bone mineral loss in HIV-infected patients treated with nelfinavir od indinavir. AIDS 2001;15:1275-80.
15. Aukrust P, Huag CJ, Ueland T, Lien E, Müller F, Espevik T et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodelling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999;84:145-50.
16. Teitelbaum S. Effect of protease inhibitors on osteoblast and osteoclast differentiation and function. Bone Metabolism and HIV Disease. Meeting Report; 2000 August 29, Washington, DC USA; 42-7.
17. Bland MJ, Altman DG. Statistics Notes. The Odds ratio. BMJ 2000;320:1468.
18. Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J et al. Bone remodelling in human immunodeficiency virus-1 infected patients. A histomorfometric study. Bone 1995;16:185-91.
19. Paton NIJ, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997;61:30-2.
20. McGowan I, Cheng A, Coleman S, Jonhson A, Genant H. Assessment of bone mineral density (BMD) in HIV-Infected antiretroviral naive patients. Eight Conference on Retroviruses and Opportunistic Infections. Conference Report; 2001 February 4-8, Chicago USA: 628.
21. Nacher M, Serrano S, Gonzàles A, Hernàndez A, Mariñoso ML, Vilella R et al. Osteoblast in HIV-infected patients: HIV-1 infection and cell function. AIDS 2001;15:2239-43.
22. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor (TNF)α and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
23. Dalgleish AG. The immune response to HIV: potential for immunotherapy? Immunol Today 1995;16:56-8.
24. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
25. Cheonis N. Osteoporosis and HIV disease. BETA 2001;14:26-34.
26. Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitam Horm 1996;52:63-98.
27. Manolagas SC. Role of cytokines in bone resorption. Bone 1995;17 Suppl 2:S63-7.
28. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993;53 Suppl 1:S94-8.
29. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-51.
30. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
31. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitor to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14: 1309-16.
32. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to protease inhibitors. AIDS 1999;13:735-7.
33. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musico M et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13: 465-71.
34. Mina J, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy sindrome. Antiviral Ther 2001;6:9-20.
35. Caron M, Auclair M, Kornprobst M, Capeau J. Indinavir-induced nuclear lamina alterations are correlated with adipocyte dysfunctions in cultured adipocytes. Antiviral Ther 2002;7 Suppl 3; L1.
36. Lenhard JM, Weiel JE, Paulik MA, Furfine ES. Stimulation of vitamin A1 acid signalling by the HIV protease inhibitor indinavir. Biochem Pharmacol 2000;59:1063-8.
37. Toma E, Devost D, Chow Lan N, Bhat PV. HIV-protease inhibitors alter retinoic acid syntesis. AIDS 2001;15:1979-84.
38. Mondy K, Yarashesky K, Powderly WG, Whyte M, Claxton S, DeMarco D et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003;36:482-90.
39. Cozzolino M, Vidal M, Arcidiacono, MV, Tebas P, Yarasheski KE, Dusso AS. HIV protease inhibitor impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-20.
40. Haug CJ, Aukrust P, Haug E, Morkrid L, Müller F, Frøland SS. Severe deficiency of 1,25-dihidroxivitamin D3 in human immunodeciciency virus infection: association with immunological hyperactivity and only minor changes in calcium omeostasis. J Clin Endocrinol Metab 1998;83:3832-8.
41. Clerici M, Trabattoni D, Piconi S, Fusi ML, Ruzzante S, Clerici C et al. A possibile role for cortisol/anticortisol imbalance in the progression of HIV. Psychoneuroendocrinology 1997;22 Suppl 1: S27-31.